The Tpl2 kinase regulates the COX-2/prostaglandin E2 axis in adipocytes in inflammatory conditions

Molecular Endocrinology

Volumn 29, Issue 7, 2015, Pages 1025-1036

  Berthou, Flavien ^a   Ceppo, Franck ^a   Dumas, Karine ^a   Massa, Fabienne ^a   Vergoni, Bastien ^a   Alemany, Susana ^b   Cormont, Mireille ^a   Tanti, Jean François ^a  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROSTAGLANDIN E2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROGRESSION LOCUS 2 KINASE; UNCLASSIFIED DRUG; ARACHIDONATE 5 LIPOXYGENASE; AUTACOID; CASPASE 3; CONDITIONED MEDIUM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; MAP3K8 PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

3T3 CELL LINE; ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COCULTURE; CONTROLLED STUDY; ENZYME INHIBITION; EXPLANT; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CONDITIONED MEDIUM; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENETICS; INFLAMMATION; MACROPHAGE ACTIVATION; METABOLISM; PATHOLOGY; PHARMACOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

MUS;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CASPASE 3; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; NF-KAPPA B; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84936094188     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1027     Document Type: Article

References (48)

1. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–445.
2. Sun S, Ji Y, Kersten S, Qi L. Mechanisms of inflammatory responses in obese adipose tissue. Annu Rev Nutr. 2012;32:261–286.
3. Exley MA, Hand L, O’Shea D, Lynch L. Interplay between the immune system and adipose tissue in obesity. J Endocrinol. 2014; 223:R41–R48.
4. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 2014;41:36–48.
5. Suganami T, Mieda T, Itoh M, Shimoda Y, Kamei Y, Ogawa Y. Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun. 2007;354:45–49.
6. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor _. Arterioscler Thromb Vasc Biol. 2005;25:2062–2068.
7. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–1772.
8. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262–1267.
9. Gonzàlez-Périz A, Claria J. Resolution of adipose tissue inflammation. Scientific WorldJournal. 2010;10:832–856.
10. Horrillo R, González-Périz A, Martínez-Clemente M, et al. 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol. 2010; 184:3978–3987.
11. Mothe-Satney I, Filloux C, Amghar H, et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes. 2012;61:2311–2319.
12. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000.
13. Fain JN, Kanu A, Bahouth SW, Cowan GS Jr, Hiler ML, Leffler CW. Comparison of PGE2, prostacyclin and leptin release by human adipocytes versus explants of adipose tissue in primary culture. Prostaglandins Leukot Essent Fatty Acids. 2002;67:467–473.
14. Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y. Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015;1851:414–421.
15. Ghoshal S, Trivedi DB, Graf GA, Loftin CD. Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice. J Biol Chem. 2011;286:889–898.
16. Hsieh PS, Lu KC, Chiang CF, Chen CH. Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats. Eur J Clin Invest. 2010;40:164–171.
17. Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, Shih KC. COX- 2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity (Silver Spring). 2009;17:1150–1157.
18. Hellmann J, Zhang MJ, Tang Y, Rane M, Bhatnagar A, Spite M. Increased saturated fatty acids in obesity alter resolution of inflammation in part by stimulating prostaglandin production. J Immunol. 2013;191:1383–1392.
19. Fujimori K, Yano M, Miyake H, Kimura H. Termination mechanism of CREB-dependent activation of COX-2 expression in early phase of adipogenesis. Mol Cell Endocrinol. 2014;384:12–22.
20. Chu X, Nishimura K, Jisaka M, Nagaya T, Shono F, Yokota K. Up-regulation of adipogenesis in adipocytes expressing stably cyclooxygenase- 2 in the antisense direction. Prostaglandins Other Lipid Mediat. 2010;91:1–9.
21. Fujimori K, Yano M, Ueno T. Synergistic suppression of early phase of adipogenesis by microsomal PGE synthase-1 (PTGES1)- produced PGE2 and aldo-keto reductase 1B3-produced PGF2α. PLoS One. 2012;7:e44698.
22. Tanti JF, Ceppo F, Jager J, Berthou F. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front Endocrinol (Lausanne). 2013;3:181.
23. Gantke T, Sriskantharajah S, Sadowski M, Ley SC. I κB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev. 2012;246:168–182.
24. Dumitru CD, Ceci JD, Tsatsanis C, et al. TNF- α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2000;103:1071–1083.
25. Rousseau S, Papoutsopoulou M, Symons A, et al. TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF α in LPS-stimulated macrophages. J Cell Sci. 2008;121:149–154.
26. Mielke LA, Elkins KL, Wei L, et al. Tumor progression locus 2 (Map3k8) is critical for host defense against listeria monocytogenes and IL-1β production. J Immunol. 2009;183:7984–7993.
27. Vougioukalaki M, Kanellis DC, Gkouskou K, Eliopoulos AG. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett. 2011;304:80–89.
28. Gantke T, Sriskantharajah S, Ley SC. Regulation and function of TPL-2, an IκB kinase-regulatedMAPkinase kinase kinase. Cell Res. 2011;21:131–145.
29. Jager J, Grémeaux T, Gonzalez T, et al. The Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate IL-1β and TNF-α effects on ERK activation and lipolysis. Diabetes. 2010;59: 61–70.
30. Ceppo F, Berthou F, Jager J, Dumas K, Cormont M, Tanti JF. Implication of the Tpl2 kinase in inflammatory changes and insulin resistance induced by the interaction between adipocytes and macrophages. Endocrinology. 2014;155:951–964.
31. Perfield JW 2nd, Lee Y, Shulman GI, et al. Tumor progression locus 2 (TPL2) regulates obesity-associated inflammation and insulin resistance. Diabetes. 2011;60:1168–1176.
32. Ballak DB, van Essen P, van Diepen JA, et al. MAP3K8 (TPL2/ COT) affects obesity-induced adipose tissue inflammation without systemic effects in humans and in mice. PLoS One. 2014;9:e89615.
33. Lancaster GI, Kowalski GM, Estevez E, et al. Tumor progression locus 2 (Tpl2) deficiency does not protect against obesity-induced metabolic disease. PLoS One. 2012;7:e39100.
34. Gómez-Casero E, San-Antonio B, Iñiguez MA, Fresno M. Cot/Tpl2 and PKCζ cooperate in the regulation of the transcriptional activity of NFATc2 through the phosphorylation of its amino-terminal domain. Cell Signal. 2007;19:1652–1661.
35. de Gregorio R, Iñiguez MA, Fresno M, Alemany S. Cot kinase induces cyclooxygenase-2 expression in T cells through activation of the nuclear factor of activated T cells. J Biol Chem. 2001;276: 27003–27009.
36. Das S, Cho J, Lambertz I, et al. Tpl2/cot signals activate ERK, JNK, and NF-κB in a cell-type and stimulus-specific manner. J Biol Chem. 2005;280:23748–23757.
37. DeCicco-Skinner KL, Nolan SJ, et al. Altered prostanoid signaling contributes to increased skin tumorigenesis in Tpl2 knockout mice. PLoS One. 2013;8:e56212.
38. Soria-Castro I, Krzyzanowska A, Pelaéz ML, et al. Cot/tpl2 (MAP3K8) mediates myeloperoxidase activity and hypernociception following peripheral inflammation. J Biol Chem. 2010;285: 33805–33815.
39. Eliopoulos AG, Dumitru CD, Wang CC, Cho J, Tsichlis PN. Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J. 2002;21:4831–4840.
40. Hatziapostolou M, Polytarchou C, Panutsopulos D, Covic L, Tsichlis PN. Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res. 2008;68:1851–1861.
41. Gavrin LK, Green N, Hu Y, et al. Inhibition of Tpl2 kinase and TNF- α production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg Med Chem Lett. 2005;15:5288–5292.
42. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1 β induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148:241–251.
43. Kilroy G, Burk DH, Floyd ZE. High efficiency lipid-based siRNA transfection of adipocytes in suspension. PLoS One. 2009;4:e6940.
44. González-Périz A, Clària J. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways. Curr Top Med Chem. 2007;7:297–309.
45. Jager J, Corcelle V, Grémeaux T, et al. Deficiency in the extracellular signal-regulated kinase 1 (ERK1) protects leptin-deficient mice from insulin resistance without affecting obesity. Diabetologia. 2011;54:180–189.
46. Roulis M, Nikolaou C, Kotsaki E, et al. Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis. Proc Natl Acad Sci USA. 2014;111:E4658–E4667.
47. Zhai B, Yang H, Mancini A, He Q, Antoniou J, Di Battista JA. Leukotriene B(4) BLT receptor signaling regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of Ras/Raf/ERK/p42 AUF1 pathway. J Biol Chem. 2010; 285:23568–23580.
48. Suganami T, Tanimoto-Koyama K, Nishida J, et al. Role of the Toll-like receptor 4/NF- κ B pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2007; 27:84–91.